Commentary

Catching up with the evidence

Author and Disclosure Information

 

References

Early last year, the US Preventive Services Task Force (USPSTF) and the American Cancer Society, among other medical groups, jointly issued guidelines for cervical cancer screening.1 In November, the American College of Obstetricians and Gynecologists followed suit,2 and the Canadian Medical Association jumped on the bandwagon early this year.3

For the first time, all agreed that no Pap smears are needed for women younger than 21 years; no testing for human papilloma virus (HPV) is necessary for women younger than 30; and for low-risk women, combined Pap smear and HPV testing can safely be done every 5 years, instead of every 3.

This is not the first time the USPSTF has told the public that less cancer screening is better. Remember the furor that accompanied its announcement that mammograms were no longer routinely recommended for women ages 40 to 49 and the downgrading of PSA screening to a D (not recommended) rating?

There is mounting evidence that more is not better in many aspects of health care. Research has shown, for example, that there is little relationship between dollars spent and quality of care for Medicare beneficiaries,4 and studies by the family physician-led Ambulatory Sentinel Practice Network have long since established that more CT scans of the head (J Fam Pract. 1993;37:129-134) and more D&Cs (J Am Board Fam Pract. 1988;1:15-23) do not lead to better outcomes. And I’ll never forget the patient—a sturdy farmer referred by a pulmonologist for cardiac catheterization—who was found to have normal coronary arteries but died of an arrhythmia on the cath table.

I doubt that we can convince our patients that less is best for cancer screening, as well as many procedures. But we can practice shared decision making, taking the time to talk to patients about the pros, cons, and trade-offs of tests and treatments and to elicit their preferences (which often differ in surprising ways from what we might guess). This approach, particularly when it’s paired with easily understood patient education material, is likely to result in fewer unnecessary—and potentially harmful—tests and treatments.

Recommended Reading

Racial gap in gastric cancer survival narrows at 3 years
MDedge Family Medicine
Shorter androgen blockade okay in localized prostate cancer
MDedge Family Medicine
Survival higher with surveillance of small kidney tumors
MDedge Family Medicine
Cancer incidence and mortality hit blacks hardest
MDedge Family Medicine
Kadcyla wins FDA approval for late-stage breast cancer
MDedge Family Medicine
Treatment-related AML rises in non-Hodgkin's lymphoma
MDedge Family Medicine
Lung cancer CT screens could save 12,000 lives
MDedge Family Medicine
Metastatic breast cancer incidence is rising among young women
MDedge Family Medicine
Colorectal cancer subtype associated with obesity, inactivity
MDedge Family Medicine
Third drug approved for metastatic, treatment-resistant GIST
MDedge Family Medicine